SC 13D/A

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person

With

Sole Voting Power

0

Shared Voting Power

0

Sole Dispositive Power

0

Shared Dispositive Power

0

SC 13D/A 1 d72183dsc13da.htm SC 13D/A SC 13D/A

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

Chembio Diagnostics, Inc.

(Name of Issuer)

Common Stock, $0.01 par value per share

(Title of Class of Securities)

163572209

(CUSIP Number)

Alexander Rakitin

Perceptive Advisors LLC

51 Astor Place, 10^th Floor

New York, NY 10003

(646) 205-5340

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

April 27, 2023

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☒

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 163572209


1.		Names of Reporting Persons. Perceptive Advisors LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

CUSIP No. 163572209


1.		Names of Reporting Persons. Perceptive Credit Advisors LLC
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

CUSIP No. 163572209


1.		Names of Reporting Persons. Joseph Edelman
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) AF
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization United States of America

CUSIP No. 163572209


1.		Names of Reporting Persons. Perceptive Credit Holdings II, L.P.
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ☐ (b) ☒
3.		SEC Use Only
4.		Source of Funds (See Instructions) WC
5.		Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ☐
6.		Citizenship or Place of Organization Delaware

Item 3.

Source and Amount of Funds or Other Consideration

Item 3 of the Schedule 13D is amended and supplemented as follows:

The Reporting Persons acquiered beneficial ownership of the shares of Common Stock in the transactions and at the prices described in Item 5(c). The source of funds for the acquisitions of the Common Stock reported on this Schedule 13D was working capital of the Credit Fund.

Item 5.

Interest in Securities of the Issuer

Item 5 of the Schedule 13D is amended and supplemented as follows:

(a)

The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference.

(b)

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

(c)

Except as previously reported in the Schedule 13D, Schedule A to this Amendment No. 2 sets forth the transactions in the Common Stock effected by the Reporting Persons during the past sixty days, and is incorporated by reference into this Item 5(c).

(d)

No person other than the Reporting Persons disclosed in this Schedule 13D is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock subject to this Schedule 13D.

(e)

Each of the Reporting Persons ceased to be beneficial owners of more than five present of the Issuer’s Common Stock on April 27, 2023.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 3, 2023

PERCEPTIVE ADVISORS LLC


By:		/s/ Joseph Edelman
Name:		Joseph Edelman
Title:		Managing Member

PERCEPTIVE CREDIT ADVISORS LLC


By:		/s/ Joseph Edelman
Name:		Joseph Edelman
Title:		Managing Member

/s/ Joseph Edelman
JOSEPH EDELMAN

PERCEPTIVE CREDIT HOLDINGS III, L.P.


By:		Perceptive Credit Opportunities GP, LLC,
		its general partner

By:		/s/ Joseph Edelman
Name:		Joseph Edelman
Title:		Managing Member

Schedule A


Name	Date of Transaction	Number of Shares Acquired or Disposed			Type of Transaction	Price per Share
Credit Fund	04/21/2023		70,200		Purchase	$	0.448
Credit Fund	04/24/2023		39,506		Purchase	$	0.45	⁽¹⁾⁽²⁾
Credit Fund	04/25/2023		113,742		Purchase	$	0.45	⁽¹⁾⁽³⁾
Credit Fund	04/27/2023		(5,162,782	)	Tender Offer⁽⁴⁾	$	0.45

⁽¹⁾	The price reported is a weighted average price. The Reporting Persons undertake to provide to the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges of the prices reported.

⁽²⁾	These shares were purchased in multiple transactions at prices ranging from $0.448 to $0.45, inclusive.

⁽³⁾	These shares were purchased in multiple transactions at prices ranging from $0.4489 to $0.46, inclusive.

⁽⁴⁾	The disposition of common stock reported herein was pursuant to the tender offer and subsequent acquisition of the Issuer completed on April 27, 2023 pursuant to the Agreement and Plan of Merger, dated as of January 31, 2023 with Biosynex SA and Project Merci Merger Sub, Inc.

SEC Form SC 13D/A filed by Chembio Diagnostics Inc. (Amendment)